Sign In
Buy ALKS
$42.76
+1.44 (+3.48%)
At Close: Jun 03, 2026
Alkermes plc Reports Third Quarter 2024 Financial Results
07:00am, Thursday, 24'th Oct 2024
— Third Quarter Revenues of $378.1 Million — — Net Sales of Proprietary Products Increased Approximately 18% Year-Over-Year — — GAAP Net Income from Continuing Operations of $92.8 Million an
Alkermes (ALKS) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
10:21am, Tuesday, 22'nd Oct 2024
Besides Wall Street's top -and-bottom-line estimates for Alkermes (ALKS), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the q
Alkermes to Report Third Quarter Financial Results on October 24, 2024
04:00pm, Thursday, 17'th Oct 2024
DUBLIN , Oct. 17, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m.
Here's Why Alkermes (ALKS) is a Strong Momentum Stock
10:56am, Friday, 11'th Oct 2024
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why Alkermes (ALKS) is a Strong Growth Stock
10:50am, Thursday, 10'th Oct 2024
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Alkermes to Host Investor Event to Review Orexin Portfolio Strategy
08:00am, Wednesday, 25'th Sep 2024
DUBLIN , Sept. 25, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that it will host an investor event for financial analysts and institutional investors on Wednesday, Oct. 9, 2024 st
Why Alkermes (ALKS) is a Top Growth Stock for the Long-Term
10:51am, Monday, 23'rd Sep 2024
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
̶ Data From Narcolepsy Type 2 Cohort of ALKS 2680 Phase 1b Study to be Presented in Oral Presentation ̶ ̶ Data From Idiopathic Hypersomnia Cohort of ALKS 2680 Phase 1b Study Accepted for Post
Here's Why Alkermes (ALKS) is a Strong Value Stock
10:41am, Friday, 20'th Sep 2024
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Alkermes Announces Launch of 7th Annual Alkermes Pathways Research Awards® Program
07:00am, Friday, 13'th Sep 2024
— Competitive Grant Program to Offer Individual Grants of Up to $100,000 per Project — — Application Period to Run From Sept. 20, 2024 Through Nov. 30, 2024 — DUBLIN , Sept.
Here's Why Alkermes (ALKS) is a Strong Growth Stock
10:45am, Thursday, 05'th Sep 2024
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Alkermes (ALKS) is a Top Value Stock for the Long-Term
10:41am, Wednesday, 04'th Sep 2024
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Alkermes to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
04:00pm, Wednesday, 28'th Aug 2024
DUBLIN , Aug. 28, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat presentation at the Morgan Stanley 22nd Annual Global Healthcar
Alkermes (ALKS) Begins Narcolepsy Type 2 Study on ALKS 2680
12:15pm, Friday, 23'rd Aug 2024
Alkermes' (ALKS) phase II Vibrance-2 study investigates the safety and efficacy of ALKS 2680 versus placebo for treating adults with narcolepsy type 2.
Alkermes Announces Initiation of Vibrance-2 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 2
07:00am, Thursday, 22'nd Aug 2024
DUBLIN , Aug. 22, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced initiation of the Vibrance-2 study, a phase 2 clinical trial evaluating the safety and efficacy of ALKS 2680 compared
